CTLA4 and Hepatitis: A prospective study on autoantibody profiles after CTLA-4 inhibition for melanoma revealed no significant relationship between these antibodies and organ-specific irAEs such as hepatitis and arthritis (10), with similar findings for brain-reactive antibodies and neurological irAEs (11).